<DOC>
	<DOCNO>NCT00711607</DOCNO>
	<brief_summary>The primary purpose trial ass pharmacokinetic profile NOMAC , E2 E1 multiple single dose administration combine oral contraceptive NOMAC-E2</brief_summary>
	<brief_title>A Trial Assess Pharmacokinetic Profile ( e.g. , Uptake , Distribution Excretion Substance Body ) Nomegestrol Acetate ( NOMAC ) , Estradiol ( E2 ) Estrone ( E1 ) After Multiple Single Dose Administration Combined Oral Contraception NOMAC-E2 ( COMPLETED ) ( P05822 )</brief_title>
	<detailed_description>This trial design assess pharmacokinetic profile NOMAC , E2 E1 multiple dose ( MD ) single dose ( SD ) administration NOMAC-E2 healthy female volunteer . In total 25 subject enter trial . These subject synchronize menstrual cycle take 1 tablet NOMAC-E2 ( 2.5 mg / 1.5 mg ) daily minimum 2 week . This follow 7-day pill-free interval . After , subject expose open-label MD treatment 1 tablet NOMAC-E2 ( 2.5 mg / 1.5 mg ) daily , 24 day . This follow second pill-free interval 10 day , allow sufficient washout NOMAC-E2 . On treatment day 35 , 20 subject receive 1 tablet NOMAC-E2 ( 2.5 mg / 1.5 mg ) 5 subject receive placebo tablet double blind setup . After treatment day 35 follow-up , subject would pill-free interval 7 day . After follow-up , subject could return contraceptive schedule . Follow-up take place treatment day 42 . Bleeding pattern tablet intake assessed mean subject diary complete daily basis . Blood sample pharmacokinetic pharmacodynamic purpose collect several time point , MD SD period . In order explore possible influence NOMAC-E2 QT/QTc interval , small placebo group design within SD period , allow comparison active-treated group . In addition several safety assessment ( vital sign , ECGs , trans vaginal ultrasound evaluation , physical , gynecological breast examination , cervical smear , routine laboratory parameter adverse event ) perform .</detailed_description>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Fertile female subject good physical mental health 18 50 year age screen Body mass index ( BMI ) 17 ≤ BMI ≤ 29 kg/m2 Able willing use nonhormonal contraceptive trial screen follow With last menstrual cycle 28 +/ 7 day Able willing sign inform consent form Able refrain smoking , grapefruit containing product , use ( methyl ) xanthine ( e.g . coffee , tea , cola , chocolate ) hospitalization pharmacokinetic sampling day 2430 day 3541 History sensitivity/idiosyncrasy NOMACE2 chemically related compound excipients could employ within study unknown drug use past Use drug substance within one week prior first treatment day , except paracetamol Clinically relevant history presence medical disorder Clinically relevant abnormal laboratory , ECG , vital sign physical finding screen ( prior dosing ) Known suspected pregnancy History of/or current abuse drug alcohol solvent , positive drug alcohol screen screen admission , judge investigator Positive test result hepatitis B surface antigen , hepatitis C antibody , HIV 1/2 serology Participation investigational drug study within 90 day prior treatment day 1 Donation blood within 90 day prior treatment day 1 Contraindications contraceptive steroid ( general ) Abnormal cervical smear screening , documentation abnormal smear perform within 12 month screen Clinically relevant transvaginal ultrasound pathology inability undergo transvaginal ultrasound evaluation Use injectable hormonal method contraception ; within 6 month injectable 3month duration , within 4 month injectable 2month duration , within 2 month injectable 1month duration Before spontaneous menstruation occur follow delivery abortion Breastfeeding within 2 month stop breast feeding prior start trial medication Present use use two month prior start trial medication follow drug : phenytoin , barbiturate , primidone , carbamazepine , oxcarbazepine , topiramate , felbamate , rifampicin , nelfinavir , ritonavir , griseofulvin , ketoconazole , sex steroid ( pre post treatment contraceptive method ) herbal remedy contain hypericum perforatum ( St. John 's Wort ) Present use use within one month prior screen agent know prolong QT/QTc interval History /or current risk factor TdP ( e.g . heart failure , hypokaliemia , hypomagnesaemia , hypocalcaemia , family history long QT syndrome , loss consciousness )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>pharmacokinetics ( PK )</keyword>
	<keyword>combine oral contraceptive</keyword>
	<keyword>nomegestrol acetate</keyword>
	<keyword>estradiol</keyword>
	<keyword>NOMAC</keyword>
	<keyword>E2</keyword>
	<keyword>NOMAC-E2</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>